TY - JOUR
T1 - Oxygen targets in comatose survivors of cardiac arrest
AU - Schmidt, Henrik
AU - Kjaergaard, Jesper
AU - Hassager, Christian
AU - Mølstrøm, Simon
AU - Grand, Johannes
AU - Borregaard, Britt
AU - Roelsgaard Obling, Laust E
AU - Venø, Søren
AU - Sarkisian, Laura
AU - Mamaev, Dmitry
AU - Jensen, Lisette O
AU - Nyholm, Benjamin
AU - Høfsten, Dan E
AU - Josiassen, Jakob
AU - Thomsen, Jakob H
AU - Thune, Jens J
AU - Lindholm, Matias G
AU - Stengaard Meyer, Martin A
AU - Winther-Jensen, Matilde
AU - Sørensen, Marc
AU - Frydland, Martin
AU - Beske, Rasmus P
AU - Frikke-Schmidt, Ruth
AU - Wiberg, Sebastian
AU - Boesgaard, Søren
AU - Lind Jørgensen, Vibeke
AU - Møller, Jacob E
N1 - Copyright © 2022 Massachusetts Medical Society.
PY - 2022/10/20
Y1 - 2022/10/20
N2 - BACKGROUND: The appropriate oxygenation target for mechanical ventilation in comatose survivors of out-of-hospital cardiac arrest is unknown.METHODS: In this randomized trial with a 2-by-2 factorial design, we randomly assigned comatose adults with out-of-hospital cardiac arrest in a 1:1 ratio to either a restrictive oxygen target of a partial pressure of arterial oxygen (Pao2) of 9 to 10 kPa (68 to 75 mm Hg) or a liberal oxygen target of a Pao2 of 13 to 14 kPa (98 to 105 mm Hg); patients were also assigned to one of two blood-pressure targets (reported separately). The primary outcome was a composite of death from any cause or hospital discharge with severe disability or coma (Cerebral Performance Category [CPC] of 3 or 4; categories range from 1 to 5, with higher values indicating more severe disability), whichever occurred first within 90 days after randomization. Secondary outcomes were neuron-specific enolase levels at 48 hours, death from any cause, the score on the Montreal Cognitive Assessment (ranging from 0 to 30, with higher scores indicating better cognitive ability), the score on the modified Rankin scale (ranging from 0 to 6, with higher scores indicating greater disability), and the CPC at 90 days.RESULTS: A total of 789 patients underwent randomization. A primary-outcome event occurred in 126 of 394 patients (32.0%) in the restrictive-target group and in 134 of 395 patients (33.9%) in the liberal-target group (hazard ratio, 0.95; 95% confidence interval, 0.75 to 1.21; P = 0.69). At 90 days, death had occurred in 113 patients (28.7%) in the restrictive-target group and in 123 (31.1%) in the liberal-target group. On the CPC, the median category was 1 in the two groups; on the modified Rankin scale, the median score was 2 in the restrictive-target group and 1 in the liberal-target group; and on the Montreal Cognitive Assessment, the median score was 27 in the two groups. At 48 hours, the median neuron-specific enolase level was 17 μg per liter in the restrictive-target group and 18 μg per liter in the liberal-target group. The incidence of adverse events was similar in the two groups.CONCLUSIONS: Targeting of a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest resulted in a similar incidence of death or severe disability or coma. (Funded by the Novo Nordisk Foundation; BOX ClinicalTrials.gov number, NCT03141099.).
AB - BACKGROUND: The appropriate oxygenation target for mechanical ventilation in comatose survivors of out-of-hospital cardiac arrest is unknown.METHODS: In this randomized trial with a 2-by-2 factorial design, we randomly assigned comatose adults with out-of-hospital cardiac arrest in a 1:1 ratio to either a restrictive oxygen target of a partial pressure of arterial oxygen (Pao2) of 9 to 10 kPa (68 to 75 mm Hg) or a liberal oxygen target of a Pao2 of 13 to 14 kPa (98 to 105 mm Hg); patients were also assigned to one of two blood-pressure targets (reported separately). The primary outcome was a composite of death from any cause or hospital discharge with severe disability or coma (Cerebral Performance Category [CPC] of 3 or 4; categories range from 1 to 5, with higher values indicating more severe disability), whichever occurred first within 90 days after randomization. Secondary outcomes were neuron-specific enolase levels at 48 hours, death from any cause, the score on the Montreal Cognitive Assessment (ranging from 0 to 30, with higher scores indicating better cognitive ability), the score on the modified Rankin scale (ranging from 0 to 6, with higher scores indicating greater disability), and the CPC at 90 days.RESULTS: A total of 789 patients underwent randomization. A primary-outcome event occurred in 126 of 394 patients (32.0%) in the restrictive-target group and in 134 of 395 patients (33.9%) in the liberal-target group (hazard ratio, 0.95; 95% confidence interval, 0.75 to 1.21; P = 0.69). At 90 days, death had occurred in 113 patients (28.7%) in the restrictive-target group and in 123 (31.1%) in the liberal-target group. On the CPC, the median category was 1 in the two groups; on the modified Rankin scale, the median score was 2 in the restrictive-target group and 1 in the liberal-target group; and on the Montreal Cognitive Assessment, the median score was 27 in the two groups. At 48 hours, the median neuron-specific enolase level was 17 μg per liter in the restrictive-target group and 18 μg per liter in the liberal-target group. The incidence of adverse events was similar in the two groups.CONCLUSIONS: Targeting of a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest resulted in a similar incidence of death or severe disability or coma. (Funded by the Novo Nordisk Foundation; BOX ClinicalTrials.gov number, NCT03141099.).
KW - Adult
KW - Humans
KW - Coma/etiology
KW - Out-of-Hospital Cardiac Arrest/complications
KW - Oxygen/administration & dosage
KW - Phosphopyruvate Hydratase/analysis
KW - Survivors
KW - Respiration, Artificial/methods
KW - Respiratory Insufficiency/etiology
KW - Biomarkers/analysis
UR - http://www.scopus.com/inward/record.url?scp=85140415254&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa2208686
DO - 10.1056/NEJMoa2208686
M3 - Journal article
C2 - 36027567
SN - 0028-4793
VL - 387
SP - 1467
EP - 1476
JO - The New England journal of medicine
JF - The New England journal of medicine
IS - 16
ER -